Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma
一项多中心 II 期临床试验的临床结果和生物标志物评估,评估尼拉帕尼联合或不联合多司他利单抗治疗复发性子宫内膜癌的效果
期刊:Nature Communications
影响因子:14.7
doi:10.1038/s41467-023-37084-w
Ainhoa Madariaga, Swati Garg, Nairi Tchrakian, Neesha C Dhani, Waldo Jimenez, Stephen Welch, Helen MacKay, Josee-Lyne Ethier, Lucy Gilbert, Xuan Li, Angela Rodriguez, Lucy Chan, Valerie Bowering, Blaise Clarke, Tong Zhang, Ian King, Gregory Downs, Tracy Stockley, Lisa Wang, Smitha Udagani, Amit M Oz